Selective 15-PGDH Inhibitor Composition for Prostaglandin Modulation

The patent applies local quality by designing inhibitors with specific molecular characteristics (aromatic rings, heteroatoms, substituents) that enable selective binding to 15-PGDH enzyme active sites while avoiding other prostaglandin-related enzymes. This structural specificity ensures the inhibitor acts locally on the target enzyme without affecting other biological systems, thereby enhancing therapeutic efficacy while minimizing off-target effects and toxicity.

The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds (such as the number and position of aromatic rings, types of heteroatoms, and nature of substituents) to optimize the balance between binding affinity to 15-PGDH and selectivity against other enzymes. By adjusting these chemical parameters, the invention achieves high therapeutic efficacy with reduced off-target effects.

The patent extracts the essential functional features required for 15-PGDH inhibition (specific molecular scaffolds with aromatic rings and heteroatoms) while eliminating unnecessary structural elements that could cause adverse reactions. By isolating and optimizing only the critical pharmacophore elements, the invention achieves high therapeutic outcomes at lower doses with minimal side effects.

The patent introduces intermediary structural elements (specific heteroatoms and substituents) that mediate between the inhibitor and the 15-PGDH enzyme, enabling high-affinity binding at low concentrations. These intermediary groups act as molecular bridges that enhance therapeutic effectiveness while reducing the required dose and consequently minimizing adverse reactions and side effects.

The patent applies universality by designing a series of 15-PGDH inhibitors with a common core structure (aromatic rings with heteroatoms) that can treat multiple disorders involving prostaglandin dysregulation, including ulcerative colitis, pulmonary hypertension, and other inflammatory conditions. This universal scaffold provides broad adaptability while maintaining high selectivity through specific substituent patterns that preserve precise enzyme binding.

The patent resolves the contradiction between versatility and selectivity by applying local quality to different substituent positions on the core molecular scaffold. By carefully selecting specific substituents at defined positions, the invention maintains high selectivity for 15-PGDH across different disease contexts, ensuring that the broad-spectrum inhibitor retains precise molecular recognition and efficacy for each specific condition.